Navigation Links
Two Metabolex Projects Recognized in Windhover's Top 10 Lists for Partnering Opportunities
Date:11/3/2008

HAYWARD, Calif., Nov. 3 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced that two of its programs (MBX-2982 and MBX-8025) have been recognized in Windhover's "Top 10 most interesting projects available for partnering" in their respective categories. MBX-2982, a potential first-in-class treatment for type 2 diabetes, was recognized in the metabolic category and MBX-8025, a potential treatment for a range of dyslipidemias, was recognized in the cardiovascular category. The selections were made by independent committees assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries.

"We are honored to receive this significant recognition for not one, but two of our current programs. This recognition underscores both MBX-2982's potential to become an important new therapy for type 2 diabetes, and MBX-8025's potential in the treatment of dyslipidemia," said Harold Van Wart, Ph.D., Chief Executive Officer of Metabolex.

The metabolic selection committee was led by Marc Wortman, contributing writer to Windhover's IN VIVO and Start-Up, and Harris Kaplan, President & CEO, and Jun Huangpu, Managing Director, of Healogix, a leading business development strategy consulting firm. The cardiovascular selection committee was led by Ed Saltzman, President, and Michael Rice, Senior Consultant, of Defined Health, a leading business development strategy consulting firm.

Drawing on the analytic resources of these organizations, the selection committees evaluated hundreds of compounds currently in development.

"Selected companies have been screened using a strict set of judging criteria for the Top 10 award and represent what our committees considered the most attractive metabolic and cardiovascular opportunities the industry has to offer," said Roger Longman, Managing Director of Windhover Information. "Winners have met rigorous criteria including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability."

Metabolex plans to present information on MBX-2982 and MBX-8025 on November 4, 2008 at Windhover's Therapeutic Area Partnerships conference in Philadelphia, PA.

MBX-2982

MBX-2982 is an agonist of GPR119, a G protein-coupled receptor that is expressed in pancreatic islets and the gastrointestinal tract. Pre-clinical studies conducted by Metabolex and others show that GPR119 agonists can stimulate glucose-dependent insulin secretion and release of incretin hormones such as GLP-1, and thus may preserve beta cell health. This novel dual mechanism may provide a unique therapeutic benefit in the treatment of type 2 diabetes. Additionally, the stimulation of GLP-1 release may mimic the benefits of incretin analogues such as exenatide (a GLP-1 analogue marketed as Byetta(R)). Unlike exenatide, however, MBX-2982 can be delivered orally.

MBX-8025

MBX-8025 is a potent, selective PPAR-delta agonist that helps to regulate fatty acid degradation, lipid storage/transport and insulin sensitivity. MBX- 8025 is being developed to treat a range of dyslipidemias, and early research suggests it may have a broader effect on a number of lipid and metabolic parameters, including triglycerides, LDL and HDL cholesterol, insulin sensitivity and inflammation.

About Windhover

Windhover Information Inc., an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO, The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see http://www.windhover.com.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has completed three Phase 2 trials; MBX-2044, which has completed a Phase 2a trial; MBX-8025, which recently completed a Phase 2 trial in patients with dyslipidemia; and MBX-2982, which recently completed a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolex Names Zhao, Martin to Executive Posts
2. Metabolex Appoints Donald Hill as Chief Financial Officer
3. Michael J. Fox Foundation Awards $2 Million Grant From EMD Serono to Research Projects on Cognitive Deficits in Parkinsons Disease
4. China Pharma Holdings, Inc. Projects 3rd Quarter 2008 Revenue Growth to Exceed 40%
5. Maryland Stem Cell Research Commission Recommends 62 Projects for Funding
6. JIC Invests in Three New Alternative Energy Projects
7. China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan
8. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
9. Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. BioTrends Research Group, Inc. Recognized as One of Philadelphias Fastest Growing Privately Held Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Market with the addition of its newest module, US Hemostats & Sealants. , ... thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... Rosalindâ„¢, the first-ever genomics analysis platform specifically designed for life science researchers ... honor of pioneering researcher Rosalind Franklin, who made a major contribution to ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
Breaking Biology Technology:
(Date:8/23/2017)... help is being enlisted in what,s thought to be the biggest study ... body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study to date of ... goal is to help advance scientific knowledge of the role of these ... The Microbiome ...
(Date:7/20/2017)... DAL ) customers now can use fingerprints instead of their ... (DCA). ... launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May at ... process to allow eligible Delta SkyMiles Members who are enrolled in CLEAR ...
(Date:6/23/2017)... ARMONK, N.Y. and ITHACA, N.Y. ... IBM ) and Cornell University, a leader in dairy ... combined with bioinformatics designed to help reduce the chances ... breaches. With the onset of this dairy project, Cornell ... the Consortium for Sequencing the Food Supply Chain, a ...
Breaking Biology News(10 mins):